Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SP100_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SP100_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/SP100_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SP100_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SP100_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SP100_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SP100_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00468231 | Oral cavity | NEOLP | negative regulation of nucleocytoplasmic transport | 8/2005 | 21/18723 | 9.62e-04 | 7.39e-03 | 8 |
GO:007259531 | Oral cavity | NEOLP | maintenance of protein localization in organelle | 12/2005 | 42/18723 | 1.13e-03 | 8.46e-03 | 12 |
GO:005105113 | Oral cavity | NEOLP | negative regulation of transport | 72/2005 | 470/18723 | 1.14e-03 | 8.49e-03 | 72 |
GO:001059414 | Oral cavity | NEOLP | regulation of endothelial cell migration | 40/2005 | 232/18723 | 1.64e-03 | 1.14e-02 | 40 |
GO:00323873 | Oral cavity | NEOLP | negative regulation of intracellular transport | 14/2005 | 58/18723 | 2.69e-03 | 1.67e-02 | 14 |
GO:004277031 | Oral cavity | NEOLP | signal transduction in response to DNA damage | 30/2005 | 172/18723 | 4.92e-03 | 2.67e-02 | 30 |
GO:005110132 | Oral cavity | NEOLP | regulation of DNA binding | 22/2005 | 118/18723 | 6.74e-03 | 3.43e-02 | 22 |
GO:200123318 | Prostate | BPH | regulation of apoptotic signaling pathway | 134/3107 | 356/18723 | 5.06e-22 | 7.84e-19 | 134 |
GO:005109818 | Prostate | BPH | regulation of binding | 121/3107 | 363/18723 | 2.74e-15 | 4.14e-13 | 121 |
GO:003450410 | Prostate | BPH | protein localization to nucleus | 98/3107 | 290/18723 | 4.78e-13 | 4.35e-11 | 98 |
GO:007233118 | Prostate | BPH | signal transduction by p53 class mediator | 64/3107 | 163/18723 | 3.51e-12 | 2.82e-10 | 64 |
GO:003238610 | Prostate | BPH | regulation of intracellular transport | 106/3107 | 337/18723 | 8.77e-12 | 6.70e-10 | 106 |
GO:009719118 | Prostate | BPH | extrinsic apoptotic signaling pathway | 77/3107 | 219/18723 | 1.67e-11 | 1.19e-09 | 77 |
GO:200123618 | Prostate | BPH | regulation of extrinsic apoptotic signaling pathway | 59/3107 | 151/18723 | 3.07e-11 | 2.02e-09 | 59 |
GO:000072314 | Prostate | BPH | telomere maintenance | 52/3107 | 131/18723 | 2.27e-10 | 1.23e-08 | 52 |
GO:005110118 | Prostate | BPH | regulation of DNA binding | 48/3107 | 118/18723 | 4.13e-10 | 2.15e-08 | 48 |
GO:003315716 | Prostate | BPH | regulation of intracellular protein transport | 76/3107 | 229/18723 | 5.05e-10 | 2.56e-08 | 76 |
GO:000691315 | Prostate | BPH | nucleocytoplasmic transport | 92/3107 | 301/18723 | 1.09e-09 | 4.84e-08 | 92 |
GO:005116915 | Prostate | BPH | nuclear transport | 92/3107 | 301/18723 | 1.09e-09 | 4.84e-08 | 92 |
GO:009013216 | Prostate | BPH | epithelium migration | 104/3107 | 360/18723 | 2.96e-09 | 1.15e-07 | 104 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SP100 | SNV | Missense_Mutation | | c.1561N>A | p.Glu521Lys | p.E521K | P23497 | protein_coding | tolerated(0.06) | benign(0.098) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SP100 | SNV | Missense_Mutation | novel | c.1863N>A | p.Phe621Leu | p.F621L | P23497 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SP100 | SNV | Missense_Mutation | | c.802N>A | p.Leu268Met | p.L268M | P23497 | protein_coding | deleterious(0.01) | probably_damaging(0.948) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SP100 | SNV | Missense_Mutation | | c.401N>G | p.Tyr134Cys | p.Y134C | P23497 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SP100 | SNV | Missense_Mutation | | c.1157N>A | p.Arg386Lys | p.R386K | P23497 | protein_coding | tolerated(0.45) | benign(0.237) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
SP100 | SNV | Missense_Mutation | rs373614701 | c.116N>T | p.Thr39Met | p.T39M | P23497 | protein_coding | deleterious(0.02) | possibly_damaging(0.821) | TCGA-BH-A0GZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
SP100 | SNV | Missense_Mutation | novel | c.1126C>T | p.Pro376Ser | p.P376S | P23497 | protein_coding | tolerated(0.59) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SP100 | SNV | Missense_Mutation | novel | c.2119G>A | p.Val707Met | p.V707M | P23497 | protein_coding | deleterious(0.04) | possibly_damaging(0.874) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SP100 | SNV | Missense_Mutation | novel | c.926N>T | p.Cys309Phe | p.C309F | P23497 | protein_coding | tolerated(0.7) | benign(0.048) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
SP100 | SNV | Missense_Mutation | novel | c.125A>G | p.Gln42Arg | p.Q42R | P23497 | protein_coding | deleterious(0.01) | benign(0.069) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |